Literature DB >> 10701468

Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine.

H Lôo1, J Saiz-Ruiz, M Ansseau, R Herrington, A Vaz-Serra, H Dilling, S de Risio.   

Abstract

BACKGROUND: Depression is treated by a great variety of antidepressant treatments. SSRIs (such as fluoxetine) are well known: it is, however, sure that further progress is needed and the search for antidepressants with other mechanisms of action (such as tianeptine) or different efficacy is still of interest.
METHODS: A multinational study compared tianeptine with fluoxetine in 387 patients with Depressive Episode, or Recurrent Depressive Disorder, or Bipolar Affective Disorder (ICD-10), in a double-blind parallel group design. They were treated for six weeks.
RESULTS: At inclusion, no significant difference between groups was shown. Final MADRS scores were 15.7 and 15.8 with tianeptine and fluoxetine, respectively (ITT population) (p = 0.944). MADRS responders were 58% and 56% with tianeptine and fluoxetine, respectively (p = 0.710). No statistical difference was observed for the other efficacy parameters. Thirty-six withdrawals occurred in each group, without any difference for the reasons of discontinuation. There was no major difference between groups for the other safety parameters.
CONCLUSIONS: In this study, both tianeptine and fluoxetine exhibited a good efficacy and safety.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10701468     DOI: 10.1016/s0165-0327(99)00009-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Discriminative stimulus properties of tianeptine.

Authors:  Tevfik Alici; Hakan Kayir; M Oguz Aygoren; Esra Saglam; I Tayfun Uzbay
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

Review 2.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine.

Authors:  Lionel Waintraub; Lucia Septien; Paul Azoulay
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Fluoxetine versus other types of pharmacotherapy for depression.

Authors:  A Cipriani; P Brambilla; T Furukawa; J Geddes; M Gregis; M Hotopf; L Malvini; C Barbui
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 5.  Neurobiological and clinical effects of the antidepressant tianeptine.

Authors:  Siegfried Kasper; Bruce S McEwen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

7.  Role of Hypothalamic-pituitary-adrenal-axis in Affective Disorders: Anti-depressant and Anxiolytic Activity of Partial 5-HT1A Agonist in Adrenalectomised Rats.

Authors:  Deepali Gupta; Mahesh Radhakrishnan; Shvetank Bhatt; Yeshwant Kurhe
Journal:  Indian J Psychol Med       Date:  2013-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.